Kadcyla Is the 'First Therapy to Show Improved Survival' in a Breast Cancer Subset

Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing neoadjuvant therapy.

Related Keywords

San Antonio ,Texas ,United States ,Neu Isenburg ,Hessen ,Germany ,German , ,Centre For Haematology ,Goethe University ,German Breast Group ,Sibylle Loibl ,Oncology Bethanien ,Antonio Breast Cancer ,San Antonio Breast Cancer Symposium ,Breast Cancer ,Sabcs ,